US · NPCE
NeuroPace, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Mountain View, CA 94043
- Website
- neuropace.com
Price · as of 2024-12-31
$17.07
Market cap 485.63M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $29.49 | +72.76% |
| Intrinsic Value(DCF) | $20.44 | +19.74% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $8.08 | $21.16 | $2.95 | $0.00 | $0.00 |
| 2022 | $3.66 | $17.78 | $0.00 | $0.00 | $0.00 |
| 2023 | $14.22 | $39.19 | $22.51 | $0.00 | $0.00 |
| 2024 | $11.00 | $29.49 | $20.30 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates NeuroPace, Inc.'s (NPCE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $29.49
- Current price
- $17.07
- AI upside
- +72.76%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$20.44
+19.74% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NPCE | NeuroPace, Inc. | $17.07 | 485.63M | +73% | +20% | — | — | -11.80 | 39.98 | 4.01 | -20.57 | — | 39.98 | 73.94% | -27.12% | -33.97% | -189.35% | -78.53% | -26.83% | 9.15 | -2.46 | 5.37 | 4.33 | -3.61 | -2677.00% | 2214.00% | -815.00% | -5.70% | -1.18 | -66.15% | 0.00% | 0.00% | 0.00% | -15.73 | -18.68 | 4.27 | -4.71 |
| ALDX | Aldeyra Therapeutics, Inc… | $5.46 | 328.49M | — | — | — | — | 0.00 | 0.00 | — | 1.55 | — | 0.00 | 0.00% | — | — | -152.98% | 0.00% | -93.94% | 0.35 | -18.51 | 2.58 | 2.52 | 1.55 | -4043.00% | — | 7717335287.00% | -9879606.86% | -1.20 | 649.97% | 0.00% | 0.00% | 16150447.97% | 1545737.39 | 1.63 | — | -8.67 |
| BWAY | BrainsWay Ltd. | $23.14 | 453.81M | +186% | +74% | -80% | -73% | 54.72 | 2.56 | 3.90 | 17.94 | — | 2.56 | 74.56% | 3.39% | 7.12% | 5.62% | -43.99% | 3.71% | 0.09 | 1.03 | 5.19 | 4.82 | -11.89 | -16923.00% | 2904.00% | -68966.00% | 4.07% | 0.67 | -243.55% | 0.00% | 0.00% | 33.58% | 69.09 | 14.78 | 2.34 | 2.84 |
| CERS | Cerus Corporation | $2.56 | 491.74M | +1,048% | -13% | — | — | -13.30 | 4.96 | 1.55 | -29.56 | — | 5.08 | 55.21% | -7.89% | -11.60% | -38.53% | -18.17% | -10.52% | 1.75 | -1.60 | 2.39 | 1.73 | -7.76 | -4762.00% | 1529.00% | -11784.00% | 3.06% | 0.18 | 10.88% | 0.00% | 0.00% | 2.34% | -20.83 | 34.77 | 1.64 | -5.07 |
| CVRX | CVRx, Inc. | $8.16 | 214.7M | +209% | -60% | — | — | -4.02 | 5.45 | 3.78 | -3.70 | — | 5.45 | 85.33% | -90.49% | -94.10% | -96.59% | -342.22% | -44.76% | 1.29 | -8.80 | 7.63 | 6.49 | 0.49 | -2302.00% | 1045.00% | 60.00% | -19.01% | -3.02 | -272.03% | 0.00% | 0.00% | 0.00% | -3.70 | -4.65 | 3.35 | -5.99 |
| DCTH | Delcath Systems, Inc. | $8.90 | 308.83M | +1,206% | — | — | — | 118.48 | 2.88 | — | 59.54 | — | 2.88 | 0.00% | — | — | 3.00% | 2.70% | 2.70% | 0.01 | — | 10.92 | 9.39 | -11.02 | -10756.00% | -10000.00% | -20899.00% | 6.56% | 2.06 | 111.33% | 0.00% | 0.00% | 3.63% | 348.16 | 10.96 | — | 10.54 |
| GNLX | Genelux Corporation | $2.98 | 112.1M | +972% | — | — | +2,543% | -4.42 | 5.03 | 16511.63 | -3.56 | — | 5.03 | -11187.50% | -396200.00% | -373362.50% | -130.58% | 1604.05% | -95.41% | 0.07 | — | 4.57 | 4.48 | 0.23 | -1810.00% | -9529.00% | 145.00% | -16.36% | -3.08 | 1093.57% | 0.00% | 0.00% | 0.00% | -3.25 | -4.77 | 12883.26 | -2.91 |
| MASS | 908 Devices Inc. | $6.90 | 249.73M | +193% | -84% | — | — | -1.30 | 0.82 | 1.58 | -0.71 | -1.49 | 1.36 | 50.18% | -128.65% | -121.09% | -51.56% | -197.59% | -39.84% | 0.06 | — | 4.10 | 3.27 | 0.85 | 8761.00% | 1872.00% | 1382.00% | -32.80% | -1.20 | -79.76% | 0.00% | 0.00% | 0.00% | -0.40 | -1.01 | 0.52 | -1.50 |
| RXST | RxSight, Inc. | $7.48 | 307.55M | +291% | -36% | -74% | — | — | 1.14 | 2.33 | -2.43 | — | 1.14 | 76.60% | -35.84% | -28.96% | 0.00% | -83.88% | 0.00% | 0.04 | -1204.75 | 10.95 | 9.58 | 0.22 | 3380.00% | -389.00% | -1360.00% | -6.17% | -0.59 | -33.66% | 0.00% | — | 1.44% | -2.00 | -4.98 | 0.72 | 3.16 |
| SENS | Senseonics Holdings, Inc. | $8.27 | 337.9M | +200% | +728% | — | — | -5.18 | -24.61 | 18.13 | -5.73 | -38.01 | -23.91 | 2.37% | -333.05% | -349.84% | -817.17% | 267.39% | -65.88% | -3.69 | -8.87 | 2.35 | 2.13 | 0.20 | 1364.00% | 37.00% | -1107.00% | -15.39% | -1.56 | 224.02% | 0.00% | 0.00% | 0.00% | -5.26 | -6.28 | 17.53 | -12.73 |
| SGHT | Sight Sciences, Inc. | $5.16 | 272.82M | +483% | -76% | — | — | -2.30 | 1.35 | 1.48 | -0.83 | — | 1.35 | 85.50% | -63.27% | -64.49% | -49.59% | -403.80% | -33.29% | 0.46 | -10.84 | 9.04 | 8.48 | 1.74 | -965.00% | -147.00% | -5261.00% | -19.22% | -1.44 | -181.68% | 0.00% | 0.00% | 0.00% | -0.76 | -1.69 | 0.48 | -1.67 |
About NeuroPace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
- CEO
- Joel D. Becker
- Employees
- 184
- Beta
- 1.86
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($20.44 ÷ $17.07) − 1 = +19.74% (DCF, example).